IONIS PHARMACEUTICALS INC's ticker is IONS and the CUSIP is 462222100. A total of 325 filers reported holding IONIS PHARMACEUTICALS INC in Q3 2018. The put-call ratio across all filers is 1.16 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $21,593,946 | +146.7% | 476,057 | +123.1% | 0.06% | +163.6% |
| Q2 2023 | $8,754,653 | +961.3% | 213,372 | +824.5% | 0.02% | +1000.0% |
| Q1 2023 | $824,879 | -89.1% | 23,080 | -88.5% | 0.00% | -91.7% |
| Q4 2022 | $7,601,855 | -41.3% | 201,267 | -31.3% | 0.02% | -45.5% |
| Q3 2022 | $12,959,000 | -37.5% | 292,994 | -47.7% | 0.04% | -35.3% |
| Q2 2022 | $20,732,000 | -28.3% | 560,031 | -28.2% | 0.07% | -20.0% |
| Q1 2022 | $28,901,000 | +59.7% | 780,256 | +31.2% | 0.08% | +117.9% |
| Q4 2021 | $18,102,000 | +71.8% | 594,885 | +89.4% | 0.04% | +62.5% |
| Q3 2021 | $10,536,000 | -13.8% | 314,134 | +2.5% | 0.02% | -14.3% |
| Q2 2021 | $12,226,000 | +46.4% | 306,488 | +65.0% | 0.03% | +27.3% |
| Q1 2021 | $8,350,000 | -11.7% | 185,720 | +11.1% | 0.02% | -18.5% |
| Q4 2020 | $9,454,000 | -79.1% | 167,205 | -82.4% | 0.03% | -83.1% |
| Q3 2020 | $45,179,000 | +25.6% | 952,136 | +56.0% | 0.16% | -10.1% |
| Q2 2020 | $35,984,000 | +38.9% | 610,311 | +11.4% | 0.18% | -15.6% |
| Q1 2020 | $25,909,000 | -33.2% | 547,997 | -14.6% | 0.21% | +80.3% |
| Q4 2019 | $38,770,000 | -2.1% | 641,785 | -2.9% | 0.12% | -12.0% |
| Q3 2019 | $39,601,000 | -53.1% | 661,005 | -49.7% | 0.13% | -53.0% |
| Q2 2019 | $84,520,000 | +32.4% | 1,315,079 | +67.2% | 0.28% | +36.7% |
| Q1 2019 | $63,833,000 | +62.3% | 786,410 | +8.1% | 0.21% | +34.4% |
| Q4 2018 | $39,331,000 | +41.3% | 727,545 | +34.8% | 0.15% | +102.6% |
| Q3 2018 | $27,836,000 | +345.5% | 539,669 | +259.9% | 0.08% | +300.0% |
| Q2 2018 | $6,248,000 | -72.0% | 149,938 | -70.4% | 0.02% | -74.3% |
| Q1 2018 | $22,303,000 | +160.6% | 505,969 | +197.3% | 0.07% | +164.3% |
| Q4 2017 | $8,559,000 | +3142.0% | 170,160 | +3164.1% | 0.03% | +2700.0% |
| Q3 2017 | $264,000 | -65.2% | 5,213 | -65.0% | 0.00% | -66.7% |
| Q2 2017 | $758,000 | -97.4% | 14,903 | -96.8% | 0.00% | -97.8% |
| Q4 2015 | $28,631,000 | – | 462,310 | – | 0.14% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bellevue Group AG | 9,930,245 | $396,117,000 | 3.87% |
| Sicart Associates LLC | 368,409 | $14,696,000 | 3.50% |
| Camber Capital Management LP | 2,000,000 | $79,780,000 | 2.69% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 181,781 | $7,251,000 | 1.91% |
| SECTOR GAMMA AS | 263,488 | $10,511,000 | 1.86% |
| Parkman Healthcare Partners LLC | 136,380 | $5,440,000 | 1.19% |
| Eversept Partners, LP | 442,000 | $17,631,380 | 1.18% |
| Affinity Asset Advisors, LLC | 75,000 | $2,992,000 | 1.07% |
| TANAKA CAPITAL MANAGEMENT INC | 16,661 | $665,000 | 0.90% |
| Sonora Investment Management, LLC | 168,665 | $6,728,000 | 0.88% |